GSK Pharma's Q2 revenue hit ₹974 Cr, a 2.6% dip due to supply constraints & GST changes.

Yet, profits (PAT) grew 3.3% to ₹253 Cr, and EBITDA climbed 4.9% to ₹335 Cr, driven by stronger margins.

EPS stands at ₹15.06 (+3%). Growth engines include robust performance in Specialty segments like newly launched Oncology products (Jemperli, Zejula) and a 13% rise in Paediatric Vaccines.

The adult immunization category for Shingrix is soaring with prescriptions up 124% YoY, a key focus area.

Strategy centers on sharpening key brand performance in General Medicines & Vaccines, expanding Oncology solutions, and leveraging digital for customer engagement.

Management highlights consistent profitability improvement from better gross margins & cost control, with ongoing portfolio transformation.